Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Pcsk9 loss of-function genetic variant is associated with pre-diabetes and diabetes

326 views

Published on

PCSK9 loss-of-function genetic variant is associated with pre-diabetes and diabetes

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Pcsk9 loss of-function genetic variant is associated with pre-diabetes and diabetes

  1. 1. PCSK9 loss-of-function genetic variant is associated with pre-diabetes and diabetes Background- Recent meta-analysis have shown a dose-dependent effect of statins therapy on the increased incidence of new-onset diabetes. PCSK9 inhibitors are the emerging lipid lowering therapies. PCSK9 loss-of-function (LOF) mutations have been associated with low LDL-C and cardiovascular risk but their impact on glucose homeostasis and the risk of diabetes is still unclear. Objective- We investigated the effect of PCSK9 LOF variant on the incidence of pre-diabetes and diabetes. YG Luna Saavedra1,2, R Dufour2, A Baass1,2 1Department of Medicine, Division of Experimental Medicine, McGill University; 2Nutrition, Metabolism and Atherosclerosis Clinic, Institut de Recherches Cliniques de Montréal (Québec, Canada) Higher frequency of diabetes/prediabetes in InsLEU-carriers Genetic variation frequency in a Familial Hypercholesterolemia cohort. (A) LDLR and (B) PCSK9 gene variations. Lower frequency of coronary events in InsLEU-carriers. (Coronary events: myocardial infarction, angina, PTCA/stenting and CABG surgery) . Conclusions : Funding: FH individuals carrying the PCSK9-InsLEU genetic variant benefit of lower risk of coronary events but, show an increased occurrence of pre-diabetes and diabetes. In light of these results, further investigation is needed to better understand the potential long- term metabolic effects of the new PCSK9-lowering therapies and the risk of new-onset diabetes. Fondation Leducq Transatlantic Network of Excellence Patients characteristics. (n) indicate the number of patients *median (ITQ) Glucose & Impaired fasting glucose assessment in InsLEU- carriers.

×